Pfizer (NYSE:PFE) has been an extremely generous company in the past when it comes to returning capital. It is not alone as a mega-cap pharma company, of course, but PFE has spent a bit more heavily than others when it comes to taking care of shareholders. The dividend gets the press - perhaps unsurprisingly - but the company has also engaged in a tremendously successful buyback over the years. In this article, we'll walk through just how well PFE has done for shareholders through its "other" capital return program.
